Background— The success of percutaneous intervention in peripheral arterial disease is
limited by restenosis. The aim of the present pilot study was to evaluate a novel method of local …

… DCB works to inhibit restenosis is still … balloons containing 3 μg drug per 1 mm 2 balloon
surface developed significant less restenosis compared with the BMS crimped on uncoated …

… restenosis in 55.3% of cases in the FAIR trial. The restenosis rate in patients treated with
uncoated balloons in … the previously reported incidences of restenosis that apply to mean lesion …

… in the group treated with uncoated balloons (55 % diabetics, 33 % restenotic lesions, median
… Paclitaxel-coated balloons inhibit restenosis without the need for stent implantation. For …

… for in-stent restenosis, a paclitaxel-coated balloon was superior to an uncoated balloon with
respect to the composite end point of target lesion failure. Paclitaxel-coated balloons are an …

… in the uncoated-balloon group and 10 in the coated-balloon … with uncoated balloons, with 6
patients having restenosis of the … Our clinical findings suggest that the inhibition of restenosis …

… Uncoated balloon PCI led to a late lumen loss of 1.85 ± 0.52 mm (n = 11) within the stented
… -up was performed to show efficacy in restenosis inhibition. In the present study only the …

… No difference in short-term tolerance between coated and uncoated balloons and no signs
… exposure of injured arteries is sufficient to inhibit restenosis during a critical period of time …

… to treatment with standard balloon catheters coated with paclitaxel, uncoated balloons
with paclitaxel dissolved in the contrast medium, or uncoated balloons without paclitaxel (control). …

… uncoated balloon. Lesion criteria for enrollment included single de novo or (non–in-stent)
restenotic … with successful balloon deployment versus for the uncoated balloon control group. …